A phase II study in patients with fludarabine refractory CLL: Dasatinib treatment combination for Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL).
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Dasatinib (Primary) ; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms Daccord
- 30 Aug 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 30 Aug 2011 Additional lead trial centre and investigators identified as reported by ClinicalTrials.gov.
- 30 Aug 2011 Planned end date changed from 16 Jul 2011 to 1 Jan 2016 as reported by ClinicalTrials.gov.